Analysts Set TherapeuticsMD Inc (TXMD) Price Target at $18.40

Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have received a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $18.40.

A number of brokerages have recently weighed in on TXMD. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price target on shares of TherapeuticsMD in a report on Monday, April 24th. Zacks Investment Research downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, May 3rd. Jefferies Group LLC set a $15.00 price target on TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, June 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $33.00 price target on shares of TherapeuticsMD in a report on Wednesday, May 10th. Finally, CIBC reiterated a “market perform” rating and issued a $12.00 price target on shares of TherapeuticsMD in a report on Tuesday, May 9th.

Shares of TherapeuticsMD (TXMD) traded up 3.18% during trading on Thursday, reaching $5.51. The company had a trading volume of 1,674,532 shares. The firm has a 50-day moving average price of $4.38 and a 200-day moving average price of $5.65. The company’s market capitalization is $1.12 billion. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.88.

ILLEGAL ACTIVITY NOTICE: “Analysts Set TherapeuticsMD Inc (TXMD) Price Target at $18.40” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2656018/analysts-set-therapeuticsmd-inc-txmd-price-target-at-18-40.html.

Large investors have recently modified their holdings of the stock. State Street Corp increased its stake in shares of TherapeuticsMD by 6.9% in the first quarter. State Street Corp now owns 3,903,491 shares of the company’s stock worth $28,105,000 after buying an additional 253,237 shares during the period. Oppenheimer & Co. Inc. increased its stake in shares of TherapeuticsMD by 94.5% in the first quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock worth $298,000 after buying an additional 20,148 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of TherapeuticsMD by 10.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock worth $4,510,000 after buying an additional 60,229 shares during the period. Geode Capital Management LLC increased its stake in shares of TherapeuticsMD by 10.1% in the first quarter. Geode Capital Management LLC now owns 1,279,601 shares of the company’s stock worth $9,213,000 after buying an additional 117,660 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock worth $70,574,000 after buying an additional 515,992 shares during the period.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:TXMD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.